Tvardi Therapeutics (TVRD) Price & Analysis

Compare

2,469 Followers

TVRD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.10 - $34.31

Previous CloseN/A

VolumeN/A

Average Volume (3M)32.57K

Market Cap

$220.92M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.03

Next Earnings

May 12, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-46.64

Shares Outstanding9,360,904

10 Day Avg. Volume25,937

30 Day Avg. Volume32,570

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$58.83

Price Target Upside147.81% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Efficacy Of TTI-101TTI-101 was superior to standard of care, repressing more IPF-induced genes.

Market PotentialTTI-101 has potential to emerge as a cornerstone therapy in the multi-billion IPF market.

Bears Say

Market CompetitionTTI-101 is the only STAT3 inhibitor in development for IPF in the US, facing scarcity value but also potential competition if alternatives emerge.

RisksThere is clinical, regulatory, financial, and commercial risk for TTI-101 and TTI-109.

Tvardi Therapeutics News

Tvardi Therapeutics reports Q2 EPS ($1.00) vs ($2.71) last year

Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi, stated, “We are on track for topline data in the...

18h ago

TVRD

Tvardi Therapeutics expects cash to fund operations into Q4 2026

Cash runway anticipated to be sufficient to fund operations into Q4 2026 Published first on TheFly – the...

18h ago

TVRD

Tvardi Therapeutics management to meet with Piper Sandler

Meeting to be held on July 22 in Boston and on July 23 in New York hosted by...

25d ago

TVRD

Tvardi Therapeutics initiated with an Outperform at Raymond James

Raymond James initiated coverage of Tvardi Therapeutics (TVRD) with an Outperform rating and $62 price target The company...

1M ago

TVRD

Tvardi Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Tvardi Therapeutics (TVRD) with an Overweight rating and $52 price target Published first...

1M ago

TVRD

Coinbase, Datadog, Tvardi, CF, Conagra: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($COIN) ), ( ($DDOG) ), ( ($TVRD) ), ( ($CF)...

2M ago

CAG

Tvardi Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Tvardi Therapeutics (TVRD) with an Overweight rating and $78 price...

2M ago

TVRD

Tvardi Therapeutics Updates Corporate Presentation on Therapies

Tvardi Therapeutics ( ($TVRD) ) has issued an announcement. On June 6, 2025, Tvardi Therapeutics updated its corporate...

2M ago

TVRD

Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks

After a rocky start to the spring, Wall Street came roaring back in May. President Trump’s softened tariff...

3M ago

TVRD

VYGR

Tvardi Therapeutics files to sell 2.08M shares of common stock for holders

16:05 EDT Tvardi Therapeutics (TVRD) files to sell 2.08M shares of common stock for holders Published first on...

3M ago

TVRD

Buy Rating for Tvardi Therapeutics Driven by Promising Phase 2 Trial Results and Growth Potential

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on TVRD stock, giving a Buy rating on May...

3M ago

TVRD

Tvardi Therapeutics completes enrollment in TTI-101 trial

Tvardi Therapeutics (TVRD) announced that it has completed enrollment for its lead program in a Phase 2 clinical...

3M ago

TVRD

Tvardi Completes Enrollment for Phase 2 IPF Trial

An update from Tvardi Therapeutics ( ($TVRD) ) is now available. On May 27, 2025, Tvardi Therapeutics announced...

3M ago

TVRD

UnitedHealth downgraded, Home Depot upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3M ago

AZO

TVRD FAQ

What was Tvardi Therapeutics Inc.’s price range in the past 12 months?

Tvardi Therapeutics Inc. lowest stock price was $8.10 and its highest was $34.31 in the past 12 months.

What is Tvardi Therapeutics Inc.’s market cap?

Tvardi Therapeutics Inc.’s market cap is $220.92M.

When is Tvardi Therapeutics Inc.’s upcoming earnings report date?

Tvardi Therapeutics Inc.’s upcoming earnings report date is May 12, 2025 which is 95 days ago.

How were Tvardi Therapeutics Inc.’s earnings last quarter?

Tvardi Therapeutics Inc. released its earnings results on Feb 26, 2025. The company reported -$1.68 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.68.

Is Tvardi Therapeutics Inc. overvalued?

According to Wall Street analysts Tvardi Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tvardi Therapeutics Inc. pay dividends?

Tvardi Therapeutics Inc. does not currently pay dividends.

What is Tvardi Therapeutics Inc.’s EPS estimate?

Tvardi Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tvardi Therapeutics Inc. have?

Tvardi Therapeutics Inc. has 9,360,904 shares outstanding.

What happened to Tvardi Therapeutics Inc.’s price movement after its last earnings report?

Tvardi Therapeutics Inc. reported an EPS of -$1.68 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.523%.

Which hedge fund is a major shareholder of Tvardi Therapeutics Inc.?

Currently, no hedge funds are holding shares in TVRD

Tvardi Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-414.88%

Trailing 12-Months

Asset Growth

-56.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tvardi Therapeutics Inc.

Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).

Tvardi Therapeutics (TVRD) Earnings & Revenues

Historic Earnings Reports

TVRD Stock 12 Month Forecast

Average Price Target

$58.83

▲(147.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","44":"$44","79":"$79","26.5":"$26.5","61.5":"$61.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$58.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$41.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,26.5,44,61.5,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.15,26.446153846153845,30.74230769230769,35.03846153846153,39.33461538461538,43.63076923076923,47.926923076923075,52.22307692307692,56.51923076923077,60.81538461538461,65.11153846153846,69.40769230769232,73.70384615384614,{"y":78,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.15,24.97153846153846,27.79307692307692,30.614615384615384,33.43615384615384,36.25769230769231,39.07923076923077,41.90076923076923,44.722307692307695,47.543846153846154,50.36538461538461,53.18692307692308,56.00846153846154,{"y":58.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.15,23.599999999999998,25.049999999999997,26.5,27.95,29.4,30.85,32.3,33.75,35.2,36.65,38.1,39.55,{"y":41,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.2,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.76,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.31,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.38,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.77,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.69,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.47,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.36,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.34,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.82,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >